Efficacy and safety of Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with hematological malignancies after highly emetogenic chemotherapy
Not Applicable
Recruiting
- Conditions
- hematological malignancies
- Registration Number
- JPRN-UMIN000005624
- Lead Sponsor
- Tokushima University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1.Hypersensitivity for Aprepitant. 2.Patient is receiving treatment with pimozide.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients with no emesis and no nausea in overall phase (0-120 hours after chemotherapy)
- Secondary Outcome Measures
Name Time Method